Schnell O, Thorsteinsdottir J, Fleischmann DF, Lenski M, Abenhardt W, Giese A, Tonn JC, Belka C, Kreth FW, Niyazi M (2016)
Publication Type: Journal article
Publication year: 2016
Book Volume: 130
Pages Range: 591-599
Journal Issue: 3
DOI: 10.1007/s11060-016-2267-x
The place of bevacizumab (BEV) in salvage re-irradiation (Re-RT) settings of malignant glioma is poorly defined. In the current study risk/benefit profiles of two BEV-based Re-RT protocols were analyzed and compared with that of salvage BEV plus irinotecan (BEV/IRI). According to interdisciplinary tumor board recommendations, patients were assigned to one of three BEV-based treatment protocols: (1) BEV/IRI, (2) Re-RT (36 Gy/18 fx) with concomitant BEV (Re-RT/BEV), and (3) Re-RT with concomitant/maintenance BEV (Re-RT/BEV→BEV). Prognostic factors were obtained from proportional hazards models. Adverse events were classified according to the NCI CTCAE, v4.0. 105 consecutive patients were enrolled from 08/2008 to 05/2014. Patients undergoing Re-RT experienced longer time intervals from initial diagnosis to BEV treatment (median: 22.0 months vs. 13.7 months, p = 0.001); those assigned to Re-RT/BEV→BEV rated better on the performance scale (median KPS
APA:
Schnell, O., Thorsteinsdottir, J., Fleischmann, D.F., Lenski, M., Abenhardt, W., Giese, A.,... Niyazi, M. (2016). Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma. Journal of Neuro-Oncology, 130(3), 591-599. https://doi.org/10.1007/s11060-016-2267-x
MLA:
Schnell, Oliver, et al. "Re-irradiation strategies in combination with bevacizumab for recurrent malignant glioma." Journal of Neuro-Oncology 130.3 (2016): 591-599.
BibTeX: Download